<div id="readability-page-1"><p>Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has earned an average rating of &#34;Moderate Buy&#34; from the sixteen research firms that are presently  covering the company, MarketBeat reports. One research analyst  has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to  the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $45.5833.</p><div><p><span></span><span>Get <strong>Beam Therapeutics</strong> alerts:</span></p></div><ul><li>MarketBeat Week in Review – 3/4 – 3/8</li></ul><p>A number of equities research analysts have recently commented on BEAM shares. HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $80.00 price target on shares of Beam Therapeutics in a research report on Friday, October 10th. Jefferies Financial Group initiated coverage on shares of Beam Therapeutics in a research note on Thursday, October 9th. They issued a &#34;buy&#34; rating and a $41.00 price target on the stock. Benchmark  reiterated a &#34;speculative buy&#34; rating on shares of Beam Therapeutics in a report on Monday, November 17th. Wall Street Zen lowered shares of Beam Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 8th. Finally, Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Beam Therapeutics in a research report on Wednesday, October 8th.</p><p><b>Read Our Latest Research Report on BEAM</b></p><h2>Beam Therapeutics Stock Down 2.3%</h2><ul><li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li></ul><p>Shares of BEAM stock opened at $26.48 on Wednesday. Beam Therapeutics has a 12-month low of $13.52 and a 12-month high of $35.25. The firm has a fifty day moving average of $24.97 and a 200-day moving average of $21.13. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of -5.98 and a beta of 2.21. </p><p>Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.12). Beam Therapeutics had a negative return on equity of 42.86% and a negative net margin of 744.41%.The business had revenue of $9.70 million for the quarter, compared to analyst estimates of $12.83 million. During the same period in the previous year, the business posted ($1.17) EPS. The business's quarterly revenue was down 32.2% compared to the same quarter last year.  Research analysts expect that  Beam Therapeutics will post -4.57 earnings per share for the current year. </p><h2>Institutional Trading of Beam Therapeutics</h2><ul><li>Is CRISPR Therapeutics the NVIDIA of gene editing?</li></ul><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC boosted its holdings in  Beam Therapeutics by 4,370.5% during the third quarter. Larson Financial Group LLC now owns 1,967 shares of the company's stock worth $48,000 after purchasing an additional 1,923 shares during the last quarter.  Van ECK Associates Corp lifted its position in  Beam Therapeutics by 48.7% during the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company's stock worth $52,000 after buying an additional 707 shares in the last quarter.  Allworth Financial LP boosted its stake in shares of  Beam Therapeutics by 7,080.0% during the 2nd quarter. Allworth Financial LP now owns 2,513 shares of the company's stock worth $43,000 after buying an additional 2,478 shares during the last quarter.  Daiwa Securities Group Inc. grew its holdings in shares of  Beam Therapeutics by 1,248.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,817 shares of the company's stock valued at $65,000 after acquiring an additional 3,534 shares in the last quarter.  Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of  Beam Therapeutics by 43.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,884 shares of the company's stock valued at $66,000 after acquiring an additional 1,175 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Beam Therapeutics</h2> (Get Free Report)<p>Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Beam Therapeutics</li><li>How to Use Stock Screeners to Find Stocks</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>How to start investing in penny stocks</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li><li>Most Volatile Stocks, What Investors Need to Know</li><li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Beam Therapeutics Right Now?</h2><p>Before you consider Beam Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.</p><p>While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BEAM

<p>Beam Therapeutics Inc. (NASDAQ:BEAM) has received a consensus "Moderate Buy" rating from sixteen research firms. Analysts have set an average 12-month target price of $45.58. The stock has varied ratings, including sell, hold, buy, and strong buy. Recent analyst reports include HC Wainwright's $80 target and Jefferies' $41 target. Beam's stock opened at $26.48, with a market cap of $2.69 billion. Institutional investors have significantly increased their holdings in Beam Therapeutics.</p>

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts